Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Market Closed 03-21 16:00:00 EDT

2.54

+0.03

+1.20%

盘后2.54

+0.000.00%

17:25 EDT

High2.56	Low2.44	Vol655.39K
Open2.47	D1 Closing2.51	Amplitude4.70%
Mkt Cap162.07M	Tradable Cap79.06M	Total Shares63.81M
T/O1.65M	T/O Rate2.11%	Tradable Shares31.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":2.54,"timestamp":1742587200000,"preClose":2.51,"halted":0,"volume":655389,"hourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.54,"latestTime":"17:25 EDT","volume":7036,"amount":17870.01,"timestamp":1742592324030},"delay":0,"floatShares":31125077,"shares":63806628,"eps":-1.150982,"marketStatus":"Market Closed","change":0.03,"latestTime":"03-21 16:00:00 EDT","open":2.47,"high":2.558,"low":2.44,"amount":1646880.0922476,"amplitude":0.047012,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.150982,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":2.51,"preHourTrading":{"tag":"盘前","latestPrice":2.4309,"preClose":2.51,"latestTime":"08:44 EDT","volume":11295,"amount":27565.8597675,"timestamp":1742561085188},"postHourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.54,"latestTime":"17:25 EDT","volume":7036,"amount":17870.01,"timestamp":1742592324030},"volumeRatio":0.6634005310327497,"impliedVol":1.1128,"impliedVolPercentile":0.456},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2519796877","title":"Larimar Therapeutics Inc  expected to post a loss of 32 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519796877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519796877?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:22","pubTimestamp":1741951328,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of32cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX0UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR"],"gpt_icon":1},{"id":"2518471593","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2518471593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518471593?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:00","pubTimestamp":1741687200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Allbirds Inc. Class A                           4Q       4:05 PM. ·Dick's Sporting Gds                              4Q      3.52   7:00 AM. ·E. W. Scripps Co                                 4Q      1.01       AMC. ·European Wax Ctr                                4Q       .06   6:00 AM. ·First Watch Rest                                4Q       .01   7:00 AM. ·Kanzhun Ltd. Sp ADR                               4Q       .22       BMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRUG","SPRB","BIRD","SID","BTMD","SKIN","AFCG","DKS","ATLC","SKYX","SSP","ACHV","MNTK","MGTX","ARCO","ONDS","QRHC","NOA","RMBL","EBR","HLLY","LEGN","ABM","WSM","KRMD","TH","BZ","PHLT","FTCI","BBCP","EXK","LRMR","AKBA","APYX","KSS","EWCZ","BLDE","KFY","S","VTS","WEST","KALV","BW","AGEN","ASRT","SMSI","ZYXI","BWAY","UNFI"],"gpt_icon":1},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVEX","BNTX","SSP","MOMO","MYPS","CVGW","BW","AEO","VTS","CINT","TBRG","KRMD","ASRT","CIEN","HLLY","BTMD","ADBE","ATLC","ARCO","KALV","LE","DRRX","BDTX","CDTX","ORCL","NKTR","FTCI","LRMR","URGN","CING","DRUG","NOA","FERG","CHRS","ZVRA","LMB","AMRN","WEST","MGTX","AURA","BBCP","LEN.B","ACET","BWMN","SFIX","AUNA","EWCZ","DKS","GECC"],"gpt_icon":1},{"id":"2512748589","title":"Larimar Therapeutics (LRMR) Gets a Buy from JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2512748589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512748589?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 22:55","pubTimestamp":1739976909,"startTime":"0","endTime":"0","summary":"In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","LRMR","BK4139","BK4127"],"gpt_icon":0},{"id":"2510303337","title":"Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m","url":"https://stock-news.laohu8.com/highlight/detail?id=2510303337","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510303337?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 18:58","pubTimestamp":1739357883,"startTime":"0","endTime":"0","summary":"The recent 14% drop in Larimar Therapeutics, Inc.'s ( NASDAQ:LRMR ) stock could come as a blow to insiders who...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/insiders-re-evaluate-their-us5220k-stock-purchase-as-larimar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LRMR","LENZ"],"gpt_icon":0},{"id":"2507824386","title":"Larimar Therapeutics Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2507824386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507824386?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:58","pubTimestamp":1738151925,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2507886682","title":"Truist sees ‘significant upside’ for Larimar Therapeutics, starts with a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507886682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507886682?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:40","pubTimestamp":1738150852,"startTime":"0","endTime":"0","summary":"As previously reported, Truist initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Despite “promising” preclin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-upside-for-larimar-therapeutics-starts-with-a-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-upside-for-larimar-therapeutics-starts-with-a-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","LENZ","BK4139"],"gpt_icon":0},{"id":"2507791681","title":"Truist Initiates Larimar Therapeutics at Buy With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2507791681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507791681?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:21","pubTimestamp":1738149678,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) has an average rating of buy and mean price target of $20.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LRMR"],"gpt_icon":0},{"id":"2507684868","title":"Larimar Therapeutics initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2507684868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507684868?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:20","pubTimestamp":1738149643,"startTime":"0","endTime":"0","summary":"Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Published first on TheFly – the ul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-initiated-with-a-buy-at-truist?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-initiated-with-a-buy-at-truist?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2505022580","title":"Larimar Therapeutics Begins Dosing Adolescents in Friedreich's Ataxia Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505022580","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505022580?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 06:29","pubTimestamp":1737671344,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) said Thursday it has begun dosing adolescents aged 12 to 17 in its pediatric pharmacokinetic, or PK, run-in study of nomlabofusp, a treatment for Friedreich's ataxia.In the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2505635026","title":"Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-in Study for Patients With Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2505635026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505635026?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 05:05","pubTimestamp":1737666301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8J7DGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2505026684","title":"Larimar Therapeutics Inc - to Initiate Cohort of Children 2-11 Years Old in 1H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505026684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505026684?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 05:05","pubTimestamp":1737666301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8J7DGP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2502706164","title":"SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2502706164","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502706164?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 23:24","pubTimestamp":1736349840,"startTime":"0","endTime":"0","summary":"Solid Biosciences Inc. SLDB announced that the FDA has cleared its investigational new drug  application to begin clinical studies on its novel AAV-based gene therapy candidate, SGT-212, for the treatment of Friedreich’s ataxia .Per the company, SGT-212 is the only full-length frataxin replacement gene therapy candidate that targets the cardiac manifestations of FA.Shares of the company were up 17.4% in after-hours trading on Jan. 7 following the announcement of the news. The stock was also up in pre-market trading on Jan. 8.In the past year, shares of Solid Biosciences have plunged 51.4% compared with the industry’s decline of 15.7%.SLDB plans to initiate a phase Ib study SGT-212 for treating FA in the second half of 2025.The first-in-human, open-label, dose-finding study will evaluate the safety and tolerability of systemic intravenous infusion and direct intradentate nuclei  infusion of SGT-212 in non-ambulatory and ambulatory adult patients with FA.In the past 60 days, estimates fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sldb-stock-fda-clears-ind-152400736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBYI","FA","IDN","LU0889565916.HKD","LU0320765992.SGD","BK4535","BK4130","BK4585","BK4139","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4532","BK4533","BK4588","BIIB","IE00B894F039.SGD","SLDB","LU0234570918.USD","BK4023","BK4157","BK4539","LRMR","LU0109394709.USD"],"gpt_icon":0},{"id":"2492295116","title":"Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492295116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492295116?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 20:45","pubTimestamp":1734439520,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report) today and set a price target of $26....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","OPY"],"gpt_icon":0},{"id":"2492959874","title":"Larimar Therapeutics announces initial data from OLE study of nomlabofusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959874","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959874?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 20:20","pubTimestamp":1734438034,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) announced initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregive","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/larimar-therapeutics-announces-initial-data-122034895.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larimar-therapeutics-announces-initial-data-122034895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2492659642","title":"Market ‘misinterpreting’ Larimar data, selloff ‘overdone,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2492659642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492659642?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 04:25","pubTimestamp":1734380748,"startTime":"0","endTime":"0","summary":"Citi analyst Samantha Semenkow notes Larimar Therapeutics (LRMR) announced initial data from the ongoing long-term Open Label Extension study evalu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/market-misinterpreting-larimar-data-selloff-overdone-says-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/market-misinterpreting-larimar-data-selloff-overdone-says-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2492648503","title":"Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492648503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492648503?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 02:10","pubTimestamp":1734372606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and As...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-larimar-therapeutics-lrmr-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-larimar-therapeutics-lrmr-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LRMR","BK4139","HCSG","ASND","LU0320765992.SGD","BK4585","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2492523612","title":"Larimar Therapeutics selloff a buying opportunity, says JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2492523612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492523612?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 01:01","pubTimestamp":1734368471,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2491697600","title":"Larimar Therapeutics trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491697600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491697600?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 22:45","pubTimestamp":1734360322,"startTime":"0","endTime":"0","summary":"09:41 EST Larimar Therapeutics (LRMR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","LENZ","BK4139"],"gpt_icon":0},{"id":"2491369762","title":"Larimar Therapeutics trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2491369762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491369762?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 22:41","pubTimestamp":1734360061,"startTime":"0","endTime":"0","summary":"09:36 EST Larimar Therapeutics (LRMR) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-trading-halted-volatility-trading-pause-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-trading-halted-volatility-trading-pause-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","LRMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.2326},{"period":"3month","weight":-0.3666},{"period":"6month","weight":-0.6407},{"period":"1year","weight":-0.7033},{"period":"ytd","weight":-0.3437}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.102481},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052852},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.133402},{"month":4,"riseRate":0.3,"avgChangeRate":-0.054337},{"month":5,"riseRate":0.5,"avgChangeRate":-0.086037},{"month":6,"riseRate":0.5,"avgChangeRate":-0.021475},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.041896},{"month":8,"riseRate":0.454545,"avgChangeRate":0.084567},{"month":9,"riseRate":0.454545,"avgChangeRate":0.010818},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.050678},{"month":11,"riseRate":0.636364,"avgChangeRate":0.050102},{"month":12,"riseRate":0.545455,"avgChangeRate":0.048319}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}